{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T16:31:09Z","timestamp":1694622669182},"reference-count":12,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2000,6,1]],"date-time":"2000-06-01T00:00:00Z","timestamp":959817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2000,6]]},"abstract":"ABSTRACT<\/jats:title>\n \n The in vitro antibacterial activities of clinafloxacin, trovafloxacin, ciprofloxacin, and cefoxitin against 1,000 clinical isolates of\n Bacteroides fragilis<\/jats:italic>\n group were compared by agar dilution in brucella blood agar (BBA) and Wilkins Chalgren agar (WCA). Significantly higher geometric mean MICs for the three quinolones and cefoxitin (\n P<\/jats:italic>\n < 0.001) were obtained in BBA than in WCA. Regardless of medium, clinafloxacin was slightly more active than trovafloxacin. The activity of clinafloxacin and trovafloxacin was greater than that of cefoxitin against\n B. distasonis<\/jats:italic>\n ,\n B. ovatus<\/jats:italic>\n , and\n B. thetaiotaomicron<\/jats:italic>\n but lower against\n B. vulgatus<\/jats:italic>\n . High cross resistance between trovafloxacin and clinafloxacin was observed.\n <\/jats:p>","DOI":"10.1128\/aac.44.6.1710-1712.2000","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T10:06:42Z","timestamp":1027764402000},"page":"1710-1712","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":9,"title":["Comparative In Vitro Activities of Clinafloxacin and Trovafloxacin against 1,000 Isolates of\n Bacteroides fragilis<\/i>\n Group: Effect of the Medium on Test Results"],"prefix":"10.1128","volume":"44","author":[{"given":"David R.","family":"Snydman","sequence":"first","affiliation":[{"name":"Departments of Medicine and Pathology and the Division of Clinical Care Research, New England Medical Center and Tufts University School of Medicine, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nilda V.","family":"Jacobus","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Pathology and the Division of Clinical Care Research, New England Medical Center and Tufts University School of Medicine, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura A.","family":"McDermott","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Pathology and the Division of Clinical Care Research, New England Medical Center and Tufts University School of Medicine, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacey E.","family":"Supran","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Pathology and the Division of Clinical Care Research, New England Medical Center and Tufts University School of Medicine, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.2.484"},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/jac\/38.2.271","article-title":"The in vitro activity of trovafloxacin and other antimicrobials against 413 anaerobic bacteria.","volume":"38","author":"Bowker K. E.","year":"1996","unstructured":"Bowker K. E. Wootton M. Holt H. A. Reeves D. S. MacGowan A. P. The in vitro activity of trovafloxacin and other antimicrobials against 413 anaerobic bacteria. J. Antimicrob. Chemother. 38 1996 271 281","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jac\/40.2.205","article-title":"In vitro activity of clinafloxacin, trovafloxacin and ciprofloxacin.","volume":"40","author":"Cohen M. A.","year":"1997","unstructured":"Cohen M. A. Huband M. D. Gage J. W. Yoderm S. L. Roland G. E. Gradcheck S. J. In vitro activity of clinafloxacin, trovafloxacin and ciprofloxacin. J. Antimicrob. Chemother. 40 1997 205 211","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0732-8893(94)00116-E","article-title":"Cross-resistance analysis for DU-6859a, a new fluoroquinolone, compared to six structurally similar compounds.","volume":"21","author":"Cormican M. G.","year":"1995","unstructured":"Cormican M. G. Marshall S. A. Jones R. N. Cross-resistance analysis for DU-6859a, a new fluoroquinolone, compared to six structurally similar compounds. Diag. Microbiol. Infect. Dis. 21 1995 51 54","journal-title":"Diag. Microbiol. Infect. Dis."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.9.2459"},{"key":"e_1_3_2_7_2","unstructured":"Eliopolous\n G. M.\n Eliopolous\n C. T.\n Quinolone antimicrobial agents: activity in vitro\n Quinolone antimicrobial agents.\n Wolfson\n J. S.\n Hooper\n D. C.\n 1989\n 45\n American Society for Microbiology\n Washington D.C."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.5.1274"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/40.4.503"},{"key":"e_1_3_2_10_2","unstructured":"National Committee for Clinical Laboratory Standards\n Methods for antimicrobial susceptibility of anaerobic bacteria: approved standard 4th Edition. NCCLS publication M11-A4\n 17\n 1997\n National Committee for Clinical Laboratory Standards\n Villanova PA"},{"issue":"3","key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1097\/00019048-199606001-00003","article-title":"Analysis of the in vitro activity of trovafloxacin (CP-99,219) against Bacteroides species.","volume":"5","author":"Snydman D. R.","year":"1996","unstructured":"Snydman D. R. McDermott L. Analysis of the in vitro activity of trovafloxacin (CP-99,219) against Bacteroides species. Infect. Dis. Clin. Pract. 5 3 Suppl. 1996 S96 S100","journal-title":"Infect. Dis. Clin. Pract."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.9.2232"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.2.428"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.44.6.1710-1712.2000","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.44.6.1710-1712.2000","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T16:53:31Z","timestamp":1645462411000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.44.6.1710-1712.2000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,6]]},"references-count":12,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2000,6]]}},"alternative-id":["10.1128\/AAC.44.6.1710-1712.2000"],"URL":"https:\/\/doi.org\/10.1128\/aac.44.6.1710-1712.2000","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,6]]},"assertion":[{"value":"1999-08-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2000-03-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2000-06-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}